Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of Quetiapine IR vs XR in Bipolar Depression
NCT00926393Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of quetiapine (extended-release tablet, brand name: Bipresso) in bipolar disorder (BD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Modified Bond-Lader Visual Analog Scale Score. Started Jun 2009; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00926393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00926393.